Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Atherosclerosis - Pipeline Review, H2 2019, provides an overview of the Atherosclerosis (Cardiovascular) pipeline landscape.
Atherosclerosis (or arteriosclerotic vascular disease) is a condition where the arteries become narrowed and hardened due to an excessive build up of plaque around the artery wall. The disease disrupts the flow of blood around the body, posing serious cardiovascular complications. Symptoms of atherosclerosis are chest pain (angina), pain in the leg, arm, and anywhere else that an artery is blocked, shortness of breath, fatigue, confusion (if the blockage affects circulation to the brain) and muscle weakness in the legs from lack of circulation.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Atherosclerosis - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Atherosclerosis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Atherosclerosis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Atherosclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Phase 0, Preclinical, Discovery and Unknown stages are 2, 2, 3, 6, 1, 36, 13 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 18 and 2 molecules, respectively.
Atherosclerosis (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Atherosclerosis (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Atherosclerosis (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Atherosclerosis (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Atherosclerosis (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Atherosclerosis (Cardiovascular)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Atherosclerosis (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Atherosclerosis (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
'
Table of Contents
Introduction
Atherosclerosis - Overview
Atherosclerosis - Therapeutics Development
Atherosclerosis - Therapeutics Assessment
Atherosclerosis - Companies Involved in Therapeutics Development
Atherosclerosis - Drug Profiles
Atherosclerosis - Dormant Projects
Atherosclerosis - Discontinued Products
Atherosclerosis - Product Development Milestones
Appendix
List of Tables
Table 1: Number of Products under Development for Atherosclerosis, H2 2019
Table 2: Number of Products under Development by Companies, H2 2019
Table 3: Number of Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 4: Number of Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Table 5: Number of Products under Development by Universities/Institutes, H2 2019
Table 6: Number of Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Table 7: Products under Development by Companies, H2 2019
Table 8: Products under Development by Companies, H2 2019 (Contd..1), H2 2019
Table 9: Products under Development by Companies, H2 2019 (Contd..2), H2 2019
Table 10: Products under Development by Companies, H2 2019 (Contd..3), H2 2019
Table 11: Products under Development by Universities/Institutes, H2 2019
Table 12: Products under Development by Universities/Institutes, H2 2019 (Contd..1), H2 2019
Table 13: Number of Products by Stage and Target, H2 2019
Table 14: Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
Table 15: Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
Table 16: Number of Products by Stage and Mechanism of Action, H2 2019
Table 17: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
Table 18: Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
Table 19: Number of Products by Stage and Route of Administration, H2 2019
Table 20: Number of Products by Stage and Molecule Type, H2 2019
Table 21: Atherosclerosis - Pipeline by 13therapeutics Inc, H2 2019
Table 22: Atherosclerosis - Pipeline by Abcentra LLC, H2 2019
Table 23: Atherosclerosis - Pipeline by ABIONYX Pharma SA, H2 2019
Table 24: Atherosclerosis - Pipeline by AFFiRiS AG, H2 2019
Table 25: Atherosclerosis - Pipeline by Allysta Pharmaceuticals Inc, H2 2019
Table 26: Atherosclerosis - Pipeline by Amgen Inc, H2 2019
Table 27: Atherosclerosis - Pipeline by Annexin Pharmaceuticals AB, H2 2019
Table 28: Atherosclerosis - Pipeline by AptaBio Therapeutics Inc, H2 2019
Table 29: Atherosclerosis - Pipeline by Artery Therapeutics Inc, H2 2019
Table 30: Atherosclerosis - Pipeline by Asdera, H2 2019
Table 31: Atherosclerosis - Pipeline by AstraZeneca Plc, H2 2019
Table 32: Atherosclerosis - Pipeline by Athera Biotechnologies AB, H2 2019
Table 33: Atherosclerosis - Pipeline by Auxagen Inc, H2 2019
Table 34: Atherosclerosis - Pipeline by Band Therapeutics LLC, H2 2019
Table 35: Atherosclerosis - Pipeline by BBN Cardio Therapeutics, H2 2019
Table 36: Atherosclerosis - Pipeline by Boehringer Ingelheim International GmbH, H2 2019
Table 37: Atherosclerosis - Pipeline by Centeer BioTherapeutics Ltd Co, H2 2019
Table 38: Atherosclerosis - Pipeline by CohBar Inc, H2 2019
Table 39: Atherosclerosis - Pipeline by Corbus Pharmaceuticals Inc, H2 2019
Table 40: Atherosclerosis - Pipeline by Daiichi Sankyo Co Ltd, H2 2019
Table 41: Atherosclerosis - Pipeline by DoNatur GmbH, H2 2019
Table 42: Atherosclerosis - Pipeline by Esperion Therapeutics Inc, H2 2019
Table 43: Atherosclerosis - Pipeline by General Regeneratives Shanghai Ltd, H2 2019
Table 44: Atherosclerosis - Pipeline by GenKyoTex SA, H2 2019
Table 45: Atherosclerosis - Pipeline by Immusoft Corp, H2 2019
Table 46: Atherosclerosis - Pipeline by Innolife Co Ltd, H2 2019
Table 47: Atherosclerosis - Pipeline by Inotrem SA, H2 2019
Table 48: Atherosclerosis - Pipeline by Inspyr Therapeutics Inc, H2 2019
Table 49: Atherosclerosis - Pipeline by Iproteos SL, H2 2019
Table 50: Atherosclerosis - Pipeline by Jenrin Discovery Inc, H2 2019
Table 51: Atherosclerosis - Pipeline by Kaleido Biosciences Inc, H2 2019
Table 52: Atherosclerosis - Pipeline by KineMed Inc, H2 2019
Table 53: Atherosclerosis - Pipeline by Kiromic Inc, H2 2019
Table 54: Atherosclerosis - Pipeline by Kowa Co Ltd, H2 2019
Table 55: Atherosclerosis - Pipeline by LG Chem Ltd, H2 2019
Table 56: Atherosclerosis - Pipeline by LipimetiX Development Inc, H2 2019
Table 57: Atherosclerosis - Pipeline by Mperia Therapeutics Inc, H2 2019
Table 58: Atherosclerosis - Pipeline by Novartis AG, H2 2019
Table 59: Atherosclerosis - Pipeline by NuSirt Biopharma Inc, H2 2019
Table 60: Atherosclerosis - Pipeline by Omeros Corp, H2 2019
List of Figures
Figure 1: Number of Products under Development for Atherosclerosis, H2 2019
Figure 2: Number of Products under Development by Companies, H2 2019
Figure 3: Number of Products under Development by Universities/Institutes, H2 2019
Figure 4: Number of Products by Top 10 Targets, H2 2019
Figure 5: Number of Products by Stage and Top 10 Targets, H2 2019
Figure 6: Number of Products by Top 10 Mechanism of Actions, H2 2019
Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
Figure 8: Number of Products by Routes of Administration, H2 2019
Figure 9: Number of Products by Stage and Routes of Administration, H2 2019
Figure 10: Number of Products by Top 10 Molecule Types, H2 2019
Figure 11: Number of Products by Stage and Top 10 Molecule Types, H2 2019
